GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹457 Cr | ₹489 Cr | ₹90 Cr | ₹94 Cr | ₹80 Cr |
What is the latest Total Non-Current Liabilities ratio of GLAND PHARMA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹457 Cr |
| Mar2024 | ₹489 Cr |
| Mar2023 | ₹90 Cr |
| Mar2022 | ₹94 Cr |
| Mar2021 | ₹80 Cr |
How is Total Non-Current Liabilities of GLAND PHARMA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹457 Cr | -6.41 | |
| Mar2024 | ₹489 Cr | 444.83 | |
| Mar2023 | ₹90 Cr | -4.57 | |
| Mar2022 | ₹94 Cr | 17.01 | |
| Mar2021 | ₹80 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹38,176.1 Cr | 5.3% | 0.3% | 36.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹446,792.0 Cr | 1.4% | 1.2% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,152.0 Cr | -0.5% | -0.6% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,915.0 Cr | 2.1% | 1.5% | 42.2% | Stock Analytics | |
| CIPLA | ₹116,354.0 Cr | 6.4% | 1.6% | -3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,681.0 Cr | 6.2% | 1.6% | 0.2% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 5.3% |
0.3% |
36.1% |
| SENSEX | -0.4% |
0.8% |
-5.3% |
You may also like the below Video Courses